A Model of Dendritic Cell Therapy for Melanoma
Authors:
Open Access
- 1 January 2013
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 41772
Abstract
Dendritic cells are a promising immunotherapy tool for boosting an individual’s antigen-specific immune response to cancer. We develop a mathematical model using differential and delay-differential equations to describe the interactions between dendritic cells, effector-immune cells, and tumor cells. We account for the trafficking of immune cells between lymph, blood, and tumor compartments. Our model reflects experimental results both for dendritic cell trafficking and for immune suppression of tumor growth in mice. In addition, in silico experiments suggest more effective immunotherapy treatment protocols can be achieved by modifying dose location and schedule. A sensitivity analysis of the model reveals which patient-specific parameters have the greatest impact on treatment efficacy.Keywords
This publication has 17 references indexed in Scilit:
- PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer VaccineClinical Cancer Research, 2011
- HUMAN T CELL RESPONSES AGAINST MELANOMAAnnual Review of Immunology, 2006
- Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretationsJournal of Theoretical Biology, 2006
- A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor GrowthCancer Research, 2005
- Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical resultsVaccine, 2005
- Dendritic Cell-Based Therapeutics for Breast CancerBreast Disease, 2004
- Determining control parameters for dendritic cell‐cytotoxic T lymphocyte interactionEuropean Journal of Immunology, 2004
- Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunityNature, 2001
- Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responsesin vitroandin vivoProceedings of the National Academy of Sciences, 1998
- Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in miceJournal of Surgical Oncology, 1998